Clinical trial · no report yet · Phase 2/Phase 3

CONCORDE trial: what clinicians have said so far

Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus

NCT01348217 ↗
Completed
Centre Georges Francois Leclerc
Deep size, estimated: 301+ verified statements

We haven't built an HCP commentary report on CONCORDE (locally advanced or inoperable esophageal carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on CONCORDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
75 posts on X
3 YouTube videos

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
Phase: Phase 2/Phase 3
Status: Completed
Conditions: Esophageal Cancer
Interventions: Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node; Boost; Boost; chemotherapy: FOLFOX 4
Arms: ARM A · Active comparator
ARM B · Experimental
Enrollment: 196
Primary outcomes: Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.
Evaluate the rate of completes endoscopic response at 3 months
Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)
Sponsor: Centre Georges Francois Leclerc with National Cancer Institute, France, UNICANCER, SFRO:French Society of Radiation Oncology, Federation Francophone de Cancerologie Digestive
Start: May 6, 2011
Primary completion: Jun 7, 2011
Results posted: No
Registry record: NCT01348217 · updated Jan 27, 2020

Publications

linked from the registry

Bednarek C, Crehange G, Quivrin M, Cueff A, Vulquin N, Chevalier C, Cerda T, Petegnief Y, Mazoyer F, Maingon P, Bosset JF, Servagi Vernat S. Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer: A posteriori analysis of the dose distribution in the sites of loco-regional relapse. Radiother Oncol. 2015 Aug;116(2):252-6. doi: 10.1016/j.radonc.2015.07.019. Epub 2015 Jul 27. PubMed 26228970

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md